For the 13th time in 14 years, Fross Zelnick was named Trademark Firm of the Year by Who’s Who Legal. Lawyers recognized by the publication were Lawrence Apolzon, Robert Becker, Stephen Bigger, Cara Boyle,More
Headlines
Fross Zelnick Hosts CLE on Ethics in Trademark Practice
Fross Zelnick’s David Donahue, Tamar Niv Bessinger, and Jessica Vosgerchian presented a practical discussion on the application of ethics rules throughout the life cycle of a trademark, including searching, registration, protection, and enforcement.More
David Donahue and Sean Harb Co-author Supreme Court Amicus Curiae Brief
David Donahue and Sean F. Harb were among the authors of the U.S. Supreme Court brief submitted by the International Trademark Association (INTA) as amicus curiae in Romag Fasteners Inc. v. Fossil Inc. INTA’s brief argues that while willfulness is an important equitable factor in determining whether to require a trademark infringer to disgorge profits,More
Allison Strickland Ricketts Provides Comments at USPTO
On behalf of Fross Zelnick, Allison Strickland Ricketts provided comments on the proposed trademark fee schedule during the public hearing of the Trademark Public Advisory Committee at the USPTO. More
Richard Lehv Quoted on “Lookalike” Models
Bloomberg Law’s Kyle Jahner quoted Richard Lehv extensively in his article about a recent case filed by Ariana Grande against fashion retailer Forever 21.More
Articles And Published Works
China and UAE: FEE REDUCTIONS
Brazil: ACCESSION TO THE MADRID PROTOCOL; NEW TRADEMARK PRACTICES
Poland: CHANGES IN TRADEMARK LAW
Certain changes to the Polish Intellectual Property Law came into force on March 16, 2019. The most significant changes were in response to EU Directive 2015/2463 of the European Parliament and of the Counsel of December 16, 2015.
Among the changes is the simplification of the renewal process.More
European Union: CLINICAL TRIALS AS GENUINE TRADEMARK USE – TIMING IS EVERYTHING
Viridis Pharmaceutical v. EUIPO, Case No. C-668/17 (July 3, 2019)
Viridis Pharmaceutical Ltd.’s (Viridis) use of BOSWELAN in connection with clinical trials for a drug to treat multiple sclerosis was held to be insufficient evidence of genuine use to defeat a non-use cancellation action against its EUTM registration for pharmaceutical and healthcare products.More
European Union: LOUBOUTIN SUCCESSFULLY DEFENDS AGAINST CANCELLATION OF RED SOLE REGISTRATION
Christian Louboutin in May 2019 walked away unscathed from another challenge to his famous Red Sole trademark, this one before the Cancellation Division of the European Union Intellectual Property Office (“EUIPO”). Competitor Van Haren Schoenen (“Van Haren”) lodged a cancellation action against the iconic designer in an attempt to boot the Red Sole off the EU trademark registry.More